Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved..
BACKGROUND AND AIMS: COVID-19 vaccination prevents severe disease in most patients with inflammatory bowel disease (IBD), but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1 year post-COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence, and identify factors associated with humoral immune response durability.
METHODS: Using a prospective cohort of COVID-19 immunized adults with IBD, we analyzed factors associated with SARS-CoV-2 infection after vaccination. We evaluated for an association between SARS-CoV-2 antibody level 12 weeks postvaccination and subsequent SARS-CoV-2 infection and assessed for a threshold of protection using receiver-operating characteristic curve analysis. We then conducted a separate analysis evaluating factors associated with persistence of SARS-CoV-2 antibodies 52 weeks postimmunization.
RESULTS: Almost half (43%) of 1869 participants developed COVID-19 after vaccination, but most infections were mild, and <1% required hospitalization. Older age and corticosteroid use were associated with a decreased risk of SARS-CoV-2 infection postvaccination (50-59 years of age vs 18-29 years of age: adjusted hazard ratio, 0.57; 95% confidence interval, 0.44-0.74; steroid users vs nonusers: adjusted hazard ratio, 0.58; 95% confidence interval, 0.39-0.87). Most (98%) participants had detectable antibody levels at 52 weeks postvaccination. Antibody levels at 12 weeks and number of vaccine doses were positively associated with higher antibody levels at 52 weeks, while anti-tumor necrosis factor α therapy was negatively associated.
CONCLUSIONS: COVID-19 vaccination generates an effective and durable protective response for the vast majority of adults with IBD, including vulnerable populations such as corticosteroid users and older individuals. Patients with IBD benefit from COVID-19 booster vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - (2024) vom: 17. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brenner, Erica J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.cgh.2024.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368592855 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368592855 | ||
| 003 | DE-627 | ||
| 005 | 20240326235448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2024.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368592855 | ||
| 035 | |a (NLM)38369224 | ||
| 035 | |a (PII)S1542-3565(24)00203-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brenner, Erica J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: COVID-19 vaccination prevents severe disease in most patients with inflammatory bowel disease (IBD), but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1 year post-COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence, and identify factors associated with humoral immune response durability | ||
| 520 | |a METHODS: Using a prospective cohort of COVID-19 immunized adults with IBD, we analyzed factors associated with SARS-CoV-2 infection after vaccination. We evaluated for an association between SARS-CoV-2 antibody level 12 weeks postvaccination and subsequent SARS-CoV-2 infection and assessed for a threshold of protection using receiver-operating characteristic curve analysis. We then conducted a separate analysis evaluating factors associated with persistence of SARS-CoV-2 antibodies 52 weeks postimmunization | ||
| 520 | |a RESULTS: Almost half (43%) of 1869 participants developed COVID-19 after vaccination, but most infections were mild, and <1% required hospitalization. Older age and corticosteroid use were associated with a decreased risk of SARS-CoV-2 infection postvaccination (50-59 years of age vs 18-29 years of age: adjusted hazard ratio, 0.57; 95% confidence interval, 0.44-0.74; steroid users vs nonusers: adjusted hazard ratio, 0.58; 95% confidence interval, 0.39-0.87). Most (98%) participants had detectable antibody levels at 52 weeks postvaccination. Antibody levels at 12 weeks and number of vaccine doses were positively associated with higher antibody levels at 52 weeks, while anti-tumor necrosis factor α therapy was negatively associated | ||
| 520 | |a CONCLUSIONS: COVID-19 vaccination generates an effective and durable protective response for the vast majority of adults with IBD, including vulnerable populations such as corticosteroid users and older individuals. Patients with IBD benefit from COVID-19 booster vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Crohn’s Disease | |
| 650 | 4 | |a Ulcerative Colitis | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Weaver, Kimberly N |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Kastl, Arthur J |e verfasserin |4 aut | |
| 700 | 1 | |a Strople, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Adler, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Dubinsky, Marla C |e verfasserin |4 aut | |
| 700 | 1 | |a Bousvaros, Athos |e verfasserin |4 aut | |
| 700 | 1 | |a Watkins, Runa |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Xiangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wenli |e verfasserin |4 aut | |
| 700 | 1 | |a Cross, Raymond K |e verfasserin |4 aut | |
| 700 | 1 | |a Higgins, Peter D R |e verfasserin |4 aut | |
| 700 | 1 | |a Ungaro, Ryan C |e verfasserin |4 aut | |
| 700 | 1 | |a Bewtra, Meenakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Bellaguarda, Emanuelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Farraye, Francis A |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, Kelly Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zikry, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bastidas, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Firestine, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Craig, Riley G |e verfasserin |4 aut | |
| 700 | 1 | |a Boccieri, Margie E |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Millie D |e verfasserin |4 aut | |
| 700 | 1 | |a Kappelman, Michael D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g (2024) vom: 17. Feb. |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:17 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2024.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 17 |c 02 | ||